Literature DB >> 18516206

Lipoprotein(a): biology and clinical importance.

Sally P A McCormick1.   

Abstract

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for developing vascular disease. Plasma Lp(a) levels above the common cut-off level of 300 mg/L place individuals at risk of developing heart disease particularly if combined with other lipid and thrombogenic risk factors. Studies in humans have shown Lp(a) levels to be hugely variable and under strict genetic control, largely by the apolipoprotein(a) [apo(a)] gene. In general, Lp(a) levels have proven difficult to manipulate, although some factors have been identified that can influence levels. Research has shown that Lp(a) has a high affinity for the arterial wall and displays many athero-thrombogenic properties. While a definite function for Lp(a) has not been identified, the last two decades of research have provided much information on the biology and clinical importance of Lp(a).

Entities:  

Year:  2004        PMID: 18516206      PMCID: PMC1853362     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN: 0159-8090


  120 in total

1.  Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: The Lugalawa Study.

Authors:  S M Marcovina; H Kennedy; G Bittolo Bon; G Cazzolato; C Galli; E Casiglia; M Puato; P Pauletto
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-05       Impact factor: 8.311

2.  An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a).

Authors:  E J Cheesman; R J Sharp; C H Zlot; C Y Liu; S Taylor; S M Marcovina; S G Young; S P McCormick
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

3.  Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans.

Authors:  S M Marcovina; J J Albers; E Wijsman; Z Zhang; N H Chapman; H Kennedy
Journal:  J Lipid Res       Date:  1996-12       Impact factor: 5.922

4.  Effect of tranexamic acid and delta-aminovaleric acid on lipoprotein(a) metabolism in transgenic mice.

Authors:  S Frank; A Hrzenjak; K Kostner; W Sattler; G M Kostner
Journal:  Biochim Biophys Acta       Date:  1999-04-19

5.  Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo.

Authors:  S Frank; M Gauster; J Strauss; A Hrzenjak; G M Kostner
Journal:  Gene Ther       Date:  2001-03       Impact factor: 5.250

6.  Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program.

Authors:  D N Kiortsis; T Tzotzas; P Giral; E Bruckert; I Beucler; S Valsamides; G Turpin
Journal:  Nutr Metab Cardiovasc Dis       Date:  2001-06       Impact factor: 4.222

7.  Physical properties of recombinant apolipoprotein(a) and its association with LDL to form an LP(a)-like complex.

Authors:  M L Phillips; A V Lembertas; V N Schumaker; R M Lawn; S J Shire; T F Zioncheck
Journal:  Biochemistry       Date:  1993-04-13       Impact factor: 3.162

8.  Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits.

Authors:  Tomonaga Ichikawa; Hiroyuki Unoki; Huijun Sun; Hiroaki Shimoyamada; Santica Marcovina; Hisataka Shikama; Teruo Watanabe; Jianglin Fan
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

9.  Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels.

Authors:  V W Armstrong; J Schleef; J Thiery; R Muche; P Schuff-Werner; T Eisenhauer; D Seidel
Journal:  Eur J Clin Invest       Date:  1989-06       Impact factor: 4.686

Review 10.  Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside.

Authors:  Santica M Marcovina; Marlys L Koschinsky
Journal:  Curr Opin Lipidol       Date:  2003-08       Impact factor: 4.776

View more
  16 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

Review 2.  Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics.

Authors:  Christopher C Imes; Melissa A Austin
Journal:  Biol Res Nurs       Date:  2012-04-23       Impact factor: 2.522

3.  Role of lipoprotein (a) in peripheral arterial disease.

Authors:  Constantine E Kosmas; Delia Silverio; Andreas Sourlas; Richard Peralta; Peter D Montan; Eliscer Guzman; Mario J Garcia
Journal:  Ann Transl Med       Date:  2019-09

4.  IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans.

Authors:  Nike Müller; Dominik M Schulte; Kathrin Türk; Sandra Freitag-Wolf; Jochen Hampe; Rainald Zeuner; Johann O Schröder; Ioanna Gouni-Berthold; Heiner K Berthold; Wilhelm Krone; Stefan Rose-John; Stefan Schreiber; Matthias Laudes
Journal:  J Lipid Res       Date:  2015-02-21       Impact factor: 5.922

Review 5.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

6.  Lipoprotein(a): Cellular Effects and Molecular Mechanisms.

Authors:  Kirsten Riches; Karen E Porter
Journal:  Cholesterol       Date:  2012-09-06

Review 7.  Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.

Authors:  Anjali Manocha; L M Srivastava
Journal:  Indian J Clin Biochem       Date:  2015-03-04

8.  Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis.

Authors:  Hong Wang; Chan E Hong; Joshua P Lewis; Yanbei Zhu; Xing Wang; Xin Chu; Joshua Backman; Ziying Hu; Peixin Yang; Christopher D Still; Glenn S Gerhard; Mao Fu
Journal:  G3 (Bethesda)       Date:  2016-11-08       Impact factor: 3.154

Review 9.  Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.

Authors:  Kush K Patel; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2021-06-12       Impact factor: 5.858

Review 10.  Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.

Authors:  Anping Cai; Liwen Li; Ying Zhang; Yujin Mo; Weiyi Mai; Yingling Zhou
Journal:  Dis Markers       Date:  2013-10-22       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.